DERIVATI DE MORFOLINA ANTAGONISTI AI RECEPTORILOR DE TAHIKININA

Price not visible for this package

Interest:

Assignment

Publication info:

No.: RO118203

Date: 28.03.2003

Inventor(s):

DORN P CONRAD [US]

FINKE PAUL E [US]

HALE JEFFREY J [US]

MACCOSS MALCOLM [US]

MILLS SANDER G [US]

SHAH SHRENIK K [US]

CHAMBERS MARK STUART [GB]

HARRISON TIMOTHY [GB]

LADDUWAHETTY TAMARA [GB]

WILLIAMS BRIAN JOHN [GB]

Applicant(s):
MERCK & CO INC [US]
Classification:
International patent classification (IPC):
A61K31/535; A61K31/5375; A61K31/5377; A61K31/54; A61K31/55; A61P1/00; A61P1/08; A61P11/00; A61P25/02; A61P25/04; A61P25/06; A61P25/08; A61P25/22; A61P25/24; A61P25/28; A61P29/00; A61P37/00; A61P9/00; A61P9/08; A61P9/10; A61P9/12; C07D265/30; C07D265/32; C07D279/12; C07D413/00; C07D413/04; C07D413/06; C07D413/14; C07D417/00; C07D417/06

Cooperative patent classification (CPC):
A61P1/00 (EP); A61P1/08 (EP); A61P11/00 (EP); A61P11/06 (EP); A61P25/02 (EP); A61P25/04 (EP); A61P25/06 (EP); A61P25/08 (EP); A61P25/22 (EP); A61P25/24 (EP); A61P25/28 (EP); A61P29/00 (EP); A61P37/00 (EP); A61P9/00 (EP); A61P9/08 (EP); A61P9/10 (EP); A61P9/12 (EP); C07D265/30 (EP, KR); C07D265/32 (EP, KR); C07D279/12 (EP); C07D413/04 (EP, KR); C07D413/06 (EP, KR); C07D413/14 (EP, KR)
Application info:
No.: RO19960001239
Date: 13.12.1994
Priority number(s):
US19930169889 17.12.1993 ; WO1994US14497 13.12.1994
Related patents:
ATE194336; AU1437595; AU701862; BG100715; BG64775; BR9408351; CA2178949; CN1057296; CN1142819; CO4340628; CY2203; CZ177296; CZ295381; DE122004000019; DE69425161; DK0734381; EP0734381; ES2147840; FI109532; FI962489; FR04C0010; GR3034095; HK1009046; HRP941000; HU224014; HUT76476; IL111960; JP3245424; JPH09506628; KR100335704; KR960706483; LTC0734381; LTPA2004002; LU91069; LV11617; MY115164; NL300146; NO2004003; NO2018011; NO308742; NO962523; NZ278222; PL182521; PL315153; PT734381; RU2201924; SA95150523; SI0734381; SK282800; SK75396; TW419471; UA47397; WO9516679; YU49037; YU74694; ZA9410008
Description:

Inventia se refera la compusi cu formula generala structurala I: sau o sare a acestora, acceptabila farmaceutic, in care R1 este ales dintre gruparile constand din: hidrogen; alchil C1-6, nesubstituit sau substituit; alchenil C2-6, nesubstituit sau substituit; alchinil C2-6; fenil, nesubstituit sau substituit; X este ales dintre gruparile constand din : -O-, -S-, -SO-, -SO2-; Y este ales dintre gruparile constand din: o legatura simpla, -O-, -S-, -CO-, -CH2-, si CR15R16; Z este alchil, C1-6 sunt antagonisti ai receptorilor de tahikinina folositi in tratamentul bolilor inflamatoare, durerii sau migrenei, astmului si emezisului si agenti de blocare a canalului de calciu, folositi in tratamentul bolilor cardiovasculare, cum ar fi angina, hipertensiune sau ischemie.

cover